Financial reports
10-Q
2023 Q3
Quarterly report
9 Nov 23
10-Q
2023 Q2
Quarterly report
8 Aug 23
10-Q
2023 Q1
Quarterly report
11 May 23
ARS
2022 FY
Annual report to shareholders
28 Apr 23
10-K
2022 FY
Annual report
15 Mar 23
10-Q
2022 Q3
Quarterly report
10 Nov 22
10-Q
2022 Q2
Quarterly report
11 Aug 22
10-K/A
2021 FY
Annual report (amended)
12 May 22
10-Q
2022 Q1
Quarterly report
12 May 22
10-K
2021 FY
Annual report
28 Mar 22
Current reports
8-K
Entry into a Material Definitive Agreement
1 Mar 24
8-K
Entry into a Material Definitive Agreement
16 Feb 24
8-K
Regulation FD Disclosure
16 Jan 24
8-K
Departure of Directors or Certain Officers
22 Nov 23
8-K
Other Events
15 Nov 23
8-K
Kinnate Biopharma Inc. Reports Third Quarter 2023 Financial Results and Recent Corporate Updates
9 Nov 23
8-K
Kinnate Biopharma Inc. Announces Pipeline Updates, Strategic Reprioritization and Workforce Restructuring
18 Sep 23
8-K
Kinnate Biopharma Inc. Reports Second Quarter 2023 Financial Results and Recent Corporate Updates
8 Aug 23
8-K
Amendments to Articles of Incorporation or Bylaws
28 Jul 23
8-K
Submission of Matters to a Vote of Security Holders
12 Jun 23
Registration and prospectus
SC 14D9/A
Tender offer solicitation (amended)
19 Mar 24
SC TO-T/A
Third party tender offer statement (amended)
19 Mar 24
SC 14D9
Tender offer solicitation
4 Mar 24
SC TO-T
Third party tender offer statement
4 Mar 24
SC14D9C
Written communication relating to third party tender offer
1 Mar 24
SC TO-C
Information about tender offer
27 Feb 24
SC14D9C
Written communication relating to third party tender offer
21 Feb 24
S-8
Registration of securities for employees
17 Mar 23
S-8
Registration of securities for employees
28 Mar 22
POS AM
Prospectus update (post-effective amendment)
28 Mar 22
Other
EFFECT
Notice of effectiveness
27 Apr 22
EFFECT
Notice of effectiveness
3 Dec 20
CORRESP
Correspondence with SEC
2 Dec 20
UPLOAD
Letter from SEC
2 Dec 20
CERT
Certification of approval for exchange listing
1 Dec 20
CORRESP
Correspondence with SEC
30 Nov 20
CORRESP
Correspondence with SEC
30 Nov 20
CORRESP
Correspondence with SEC
30 Nov 20
UPLOAD
Letter from SEC
23 Nov 20
CORRESP
Correspondence with SEC
16 Nov 20
Ownership
4
Neha Krishnamohan
5 Mar 24
4
Mark A Meltz
5 Mar 24
4
Richard Thomas Williams
5 Mar 24
SC 13D/A
Foresite Capital Fund V, L.P.
22 Feb 24
SC 13D/A
ORBIMED ADVISORS LLC
21 Feb 24
SC 13G/A
Nextech V Oncology S.C.S., SICAV-SIF
14 Feb 24
SC 13G/A
TANG CAPITAL PARTNERS LP
14 Feb 24
SC 13G/A
Lynx1 Capital Management LP
14 Feb 24
4
Richard Thomas Williams
5 Dec 23
4
Neha Krishnamohan
5 Dec 23